ReviewCurrent pharmaceutical design2013
Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives.
Review in Current pharmaceutical design, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Stromal cells and epigenetics: emerging key players of chronic inflammatory skin diseases.BMB reports · 2024Review
- MicroRNAs overexpressed in Crohn's disease and their interactions with mechanisms of epigenetic regulation explain novel aspects of Crohn's disease pathogenesis.Clinical epigenetics · 2021Review
- BET protein inhibitor JQ1 downregulates chromatin accessibility and suppresses metastasis of gastric cancer via inactivating RUNX2/NID1 signaling.Oncogenesis · 2020Article
- Small molecule KDM4s inhibitors as anti-cancer agents.Journal of enzyme inhibition and medicinal chemistry · 2018Article
- The Curtius Rearrangement: Applications in Modern Drug Discovery and Medicinal Chemistry.ChemMedChem · 2018Review
- Metabolic Response to XD14 Treatment in Human Breast Cancer Cell Line MCF-7.International journal of molecular sciences · 2016Article
- Transcriptome sequencing reveals that LPS-triggered transcriptional responses in established microglia BV2 cell lines are poorly representative of primary microglia.Journal of neuroinflammation · 2016Article
- Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.Oncotarget · 2016Article
- Transcriptome sequencing of microglial cells stimulated with TLR3 and TLR4 ligands.BMC genomics · 2015Article
- Targeting Histone Deacetylases in Diseases: Where Are We?Antioxidants & redox signaling · 2015Review
- Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma.International journal of cancer · 2015Article
- Epigenetic Alterations in Fanconi Anaemia: Role in Pathophysiology and Therapeutic Potential.PloS one · 2015Article
- Dual RNA sequencing reveals the expression of unique transcriptomic signatures in lipopolysaccharide-induced BV-2 microglial cells.PloS one · 2015Article
- Computer-aided Molecular Design of Compounds Targeting Histone Modifying Enzymes.Computational and structural biotechnology journal · 2015Review
- Potential of epigenetic therapies in the management of solid tumors.Cancer management and research · 2015Review
- Genome-wide analysis of antiviral signature genes in porcine macrophages at different activation statuses.PloS one · 2014Article
- Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib.Molecular oncology · 2013Article
- Rejuvenating sirtuins: the rise of a new family of cancer drug targets.Current pharmaceutical design · 2013Review
- Chemoinformatic analysis of GRAS (Generally Recognized as Safe) flavor chemicals and natural products.PloS one · 2012Article
- An RNA-seq-Based Expression Profiling of Radiation-Induced Esophageal Injury in a Rat Model.Dose-response : a publication of International Hormesis SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Research on cancer epigenetics has flourished in the last decade. Nevertheless growing evidence point on the importance to understand the mechanisms by which epigenetic changes regulate the genesis and progression of cancer growth. Several epigenetic targets have been discovered and are currently under validation for new anticancer therapies. Drug discovery approaches aiming to target these epigenetic enzymes with small-molecules inhibitors have produced the first pre-clinical and clinical outcomes and many other compounds are now entering the pipeline as new candidate epidrugs. The most studied targets can be ascribed to histone deacetylases and DNA methyltransferases, although several other classes of enzymes are able to operate post-translational modifications to histone tails are also likely to represent new frontiers for therapeutic interventions. By acknowledging that the field of cancer epigenetics is evolving with an impressive rate of new findings, with this review we aim to provide a current overview of pre-clinical applications of smallmolecules for cancer pathologies, combining them with the current knowledge of epigenetic targets in terms of available structural data and drug design perspectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.